Medicine, Hematology Oncology Division

Grants

Grants per year 1995 2007 2008 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2028

• 468 Active
• 1104 Finished

Grants per year

Search results

• Treating cognitive impairments in cancer patients via systematic light exposure

  Wu, L. M., Mehta, J., Mroczek, D. K., Penedo, F. J. & Zee, P. C.

  National Cancer Institute

  11/20/15 → 10/16/19

  Project: Research project

  • Cognitive Dysfunction 100%
  • Light 61%
  • Neoplasms 44%
  • Sleep 22%
  • Hematopoietic Stem Cells 21%

• Targeting alpha B-Crystallin in Basal-like Breast Cancer

  Gradishar, W. J.

  University of Wisconsin-Madison, Breast Cancer Research Foundation

  10/1/18 → 9/30/19

  Project: Research project

  • alpha-Crystallin B Chain 100%
  • Breast Neoplasms 64%
  • Crystallins 61%
  • Neoplasm Metastasis 38%
  • Breast 23%

• PARP inhibition and tumor immunity

  Zhang, B., Fang, D. & Sosman, J. A.

  AbbVie Inc.

  9/29/17 → 9/29/19

  Project: Research project

  • Poly(ADP-ribose) Polymerase Inhibitors 100%
  • Myeloid-Derived Suppressor Cells 50%
  • Immunity 38%
  • veliparib 32%
  • Neoplasms 21%

• Prot #D4190C00010: A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors

  Carneiro Filho, B. A.

  PRA Health Sciences, MedImmune, LLC

  9/20/16 → 9/20/19

  Project: Research project

• Prot #AZA-MDS-003: A Phase 3, Multicenter, Randomized, Doubleblind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects with Red Blood Cell Transfusion-Dependent Anemia

  Frankfurt, O.

  Celgene Corporation

  9/17/13 → 9/17/19

  Project: Research project

• Prot #CC-122-DLBCL-001: A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma

  Karmali, R. & Kaplan, J. B.

  Celgene Corporation

  9/17/13 → 9/17/19

  Project: Research project

• Prot #CC-486-AML-001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in

  Frankfurt, O.

  Celgene Corporation

  9/13/13 → 9/13/19

  Project: Research project

• Executive Officer Grant Agreement

  Dinner, S. N.

  Alliance Foundation Trials, LLC

  9/1/17 → 8/31/19

  Project: Research project

  • Meals 100%
  • Budgets 84%
  • Pharmaceutical Research 52%
  • Telecommunications 51%
  • Triage 41%

• Targeting BET Bromodomain in Pancreatic Cancer

  Munshi, H. G. & Bentrem, D. J.

  National Cancer Institute

  9/15/14 → 8/31/19

  Project: Research project

  • Adenocarcinoma 100%
  • Protein Domains 97%
  • Pancreatic Neoplasms 69%
  • varespladib methyl 42%
  • Collagen 38%

• Signal Transduction of Type 1 Interferons in Malignant Cells

  Platanias, L. C.

  National Cancer Institute

  9/1/16 → 8/31/19

  Project: Research project

• MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies

  Crispino, J. D., Altman, J. K., Giles, F. J., Stein, B. L. & Wen, Q.

  Leukemia & Lymphoma Society

  10/1/14 → 8/31/19

  Project: Research project

  • Aurora Kinase A 100%
  • MLN 8237 99%
  • Leukemia, Megakaryoblastic, Acute 88%
  • Primary Myelofibrosis 70%
  • Neoplasms 21%

• Subproject for Diversity Supplement to R01 Parent Grant CA186885

  Munshi, H. G.

  National Cancer Institute

  9/15/14 → 8/31/19

  Project: Research project

  • Adenocarcinoma 100%
  • Protein Domains 97%
  • varespladib methyl 42%
  • Collagen 38%
  • Fibrosis 26%

• Prot #ABI-007-PANC-009: An Open-Label, Multicenter, Single-Arm, Phase 1/2 Study Of Metronomic 5-Fluorouracil In Combination With Nabpaclitaxel, Bevacizumab, Leucovorin, And Oxaliplatin In Patients With Metastatic Pancreatic Adenocarcinoma

  Kalyan, A.

  INC Research, LLC, Celgene Corporation

  8/10/16 → 8/10/19

  Project: Research project

• VA IPA for Elspeth Beauchamp

  Platanias, L. C. & Beauchamp, E. M.

  Jesse Brown VA Medical Center

  10/1/15 → 7/31/19

  Project: Research project

  • Job Description 100%
  • Immunoblotting 63%
  • Transfection 55%
  • Molecular Biology 52%
  • Phosphotransferases 50%

• GATA1 Mutation in Defective Erythropoiesis

  Crispino, J. D.

  National Institute of Diabetes and Digestive and Kidney Diseases

  8/1/16 → 7/31/19

  Project: Research project

• ECOG-ACRIN NCI Community Oncology Research Program (NCORP) Research Base Grant

  Cella, D., Benson III, A. B., Bentrem, D. J., Kircher, S. M., Pearman, T. P., Penedo, F. J., Simon, M. A., Tegel, K. K., Yanez, B. R. & Bilimoria, K. Y.

  ECOG-ACRIN Medical Research Foundation, Inc., National Cancer Institute

  8/1/14 → 7/31/19

  Project: Research project

• Assessing the Effect of Specific TGF-B1 Inhibitor in Myelofibrosis

  Crispino, J. D.

  Scholar Rock, Inc.

  6/8/18 → 7/31/19

  Project: Research project

  • animal models 100%

• Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma

  Winter, J. N.

  Joan and Sanford I. Weill Medical College of Cornell University, National Cancer Institute

  8/6/14 → 7/31/19

  Project: Research project

  • Germinal Center 100%
  • Lymphoma 93%
  • B-Cell Lymphoma 87%
  • Cell Line 66%
  • RNA-Seq 65%

• ECOG-ACRIN NCORP Research Base: Cancer Care Delivery Research (CCDR)

  Cella, D., Benson III, A. B., Bentrem, D. J., Bilimoria, K. Y. & Pearman, T. P.

  ECOG-ACRIN Medical Research Foundation, Inc., National Cancer Institute

  8/1/14 → 7/31/19

  Project: Research project

  • Neoplasms 100%
  • Research Personnel 96%
  • Congresses 68%
  • Group Processes 43%
  • Manuscripts 39%

• Prot #ADU-CL-11: A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination with Epacadostat in Adults with Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer

  Matei, D. E.

  Medpace, Inc., Aduro Biotech, Inc

  7/19/16 → 7/19/19

  Project: Research project

• Prot #CA212001: A Phase 1, Open-label, Multicenter Study of BMS-936564 (MDX-1338) in Subjects with Relapsed Acute Myelogenous Leukemia and selected B-cell malignancies

  Altman, J. K.

  Bristol-Myers Squibb Company

  7/15/13 → 7/15/19

  Project: Research project

• Prot #RAP-CLT-15-010: A Prospective Observational Trial Evaluating Outcomes of FoundationOne®-Directed Matched Targeted Therapy in Patients with Cancer of Unknown Primary (CUP)

  Chandra, S.

  Vector Oncology Solutions, LLC, Foundation Medicine, Inc.

  7/13/16 → 7/13/19

  Project: Research project

• Prot #E7777-G000-302: A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

  Kuzel, T. M.

  Clinical Financial Services, LLC, Eisai, Inc.

  7/1/13 → 7/1/19

  Project: Research project

• Prot# 104532: Pilot Neoadjuvant Trial in Breast Cancer with Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib) (NU Prot# NU 05B2)

  Gradishar, W. J.

  GlaxoSmithKline plc

  11/29/05 → 7/1/19

  Project: Research project

• Prot# H3E-US-X032//NU 03L3: A Phase I/II Trial of Induction Cisplatin and Pemetrexed in Patients with Stage III Non-Small Cell Lung Cancer Followed by Surgery or Chemoradiation

  Patel, J. D., Becker, F. S., Hart, E. M. & Hoffman Marymont, M.

  Lilly Research Laboratories

  1/26/05 → 7/1/19

  Project: Research project